- Home
- LIDR vs CYCN Comparison
LIDR vs CYCN Comparison
Compare LIDR & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- CYCN
- Stock Information
- Founded
- LIDR 2013
- CYCN 2018
- Country
- LIDR United States
- CYCN United States
- Employees
- LIDR N/A
- CYCN N/A
- Industry
- LIDR Auto Parts:O.E.M.
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- LIDR Consumer Discretionary
- CYCN Health Care
- Exchange
- LIDR Nasdaq
- CYCN Nasdaq
- Market Cap
- LIDR 9.8M
- CYCN 8.4M
- IPO Year
- LIDR N/A
- CYCN N/A
- Fundamental
- Price
- LIDR $0.77
- CYCN $2.82
- Analyst Decision
- LIDR Hold
- CYCN
- Analyst Count
- LIDR 1
- CYCN 0
- Target Price
- LIDR N/A
- CYCN N/A
- AVG Volume (30 Days)
- LIDR 961.6K
- CYCN 5.8M
- Earning Date
- LIDR 02-20-2025
- CYCN 03-04-2025
- Dividend Yield
- LIDR N/A
- CYCN N/A
- EPS Growth
- LIDR N/A
- CYCN N/A
- EPS
- LIDR N/A
- CYCN N/A
- Revenue
- LIDR $225,000.00
- CYCN $194,000.00
- Revenue This Year
- LIDR N/A
- CYCN N/A
- Revenue Next Year
- LIDR $2,650.00
- CYCN N/A
- P/E Ratio
- LIDR N/A
- CYCN N/A
- Revenue Growth
- LIDR N/A
- CYCN N/A
- 52 Week Low
- LIDR $0.75
- CYCN $1.27
- 52 Week High
- LIDR $5.15
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- LIDR 39.04
- CYCN 43.92
- Support Level
- LIDR $0.78
- CYCN $2.89
- Resistance Level
- LIDR $0.99
- CYCN $4.80
- Average True Range (ATR)
- LIDR 0.08
- CYCN 0.66
- MACD
- LIDR 0.01
- CYCN -0.13
- Stochastic Oscillator
- LIDR 6.79
- CYCN 6.03
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.